Baird analyst Eric Coldwell upgraded Iqvia (IQV) to Outperform from Neutral with a price target of $258, up from $224. The firm sees a “moderately improving environment” for the company and likes its longer-term opportunity. There are limited ways investors can directly play a clinical, commercial research and development recovery and Iqvia seems “to be taking more steps forward than backward,” the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- IQVIA Holdings Reports Strong Q3 2025 Results
- IQVIA Holdings: Strong Earnings and Strategic Growth
- Iqvia sees Q4 adjusted EPS $3.35-$3.45, consensus $3.39
- IQVIA Holdings: Hold Rating Amid Stable Performance and Limited Upside Potential
- Resilient Growth and Strong Segment Performance Drive Buy Rating for IQVIA Holdings